Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2023 it was -$13.49M, down 193.3% from the year before. The highest annual figure on record is $8.12B in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$13.49M | -193.3% |
| FY2022 | Dec 31, 2022 | $14.47M | -99.8% |
| FY2021 | Dec 31, 2021 | $8.12B | +7259.1% |
| FY2020 | Dec 31, 2020 | $110.37M | +145.7% |
| FY2019 | Dec 31, 2019 | $44.93M | +106.3% |
| FY2018 | Dec 31, 2018 | $21.78M | -15.6% |
| FY2017 | Dec 31, 2017 | $25.81M | – |
| FY2016 | Dec 31, 2016 | -$596.00K | – |
| FY2015 | Dec 31, 2015 | -$1.42M | – |
| FY2014 | Dec 31, 2014 | -$1.52M | -120.4% |
| FY2013 | Dec 31, 2013 | $7.44M | – |
| FY2011 | Dec 31, 2011 | -$844.70K | – |
| FY2010 | Dec 31, 2010 | -$8.51M | -142.6% |
| FY2009 | Dec 31, 2009 | $19.96M | – |
See a number that looks wrong?